EIF2AK4 mutation in pulmonary veno-occlusive disease: A case report and review of the literature.
BACKGROUND
Pulmonary veno-occlusive disease (PVOD) is a rare and devastating cause of pulmonary arterial hypertension with a non-specific clinical presentation and a relatively specific presentation in high-resolution thoracic CT scan images. Definitive diagnosis is made by histological examination in previous. According to the 2015 ESC/ERS Guidelines, detection of a mutation in the eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4) without histological confirmation is recommended to validate the diagnosis of PVOD.


METHODS
We report the case of a 27-year-old man who was admitted for persistent cough and dyspnea that had lasted for 5 months and had developed and experienced progressive dyspnea for the last 2 months. The echocardiogram and right heart catheterization without vasodilator challenge confirmed the diagnosis of pulmonary arterial hypertension. Other tests, such as high-resolution thoracic CT scan, V/Q scan, pulmonary function test with diffusion capacity, and blood tests, excluded other associated diseases which could have caused pulmonary hypertension.


RESULTS
The initial diagnosis at admission was idiopathic pulmonary arterial hypertension and an oral vasodilator (sildenafil) was given. However, the dyspnea subsequently worsened, and the patient was transferred to a regional lung transplant center, where he died of heart failure 1 week later. Using exome sequencing, we found an EIF2AK4 mutation, which was sufficient to confirm the diagnosis of PVOD.


CONCLUSIONS
This is the first reported case of EIF2AK4 mutation in PVOD in a Chinese patient population. We found the frameshift EIF2AK4 mutation c.1392delT (p.Arg465fs) in this case. Up to now, there has been a paucity of data on this rare disease, and the exact role of EIF2AK4 loss-of-function mutations in the pathogenesis of PVOD is still unknown. More investigations should be conducted in the future.
Department of Respiratory medicine, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Li
L
Liang
Guofeng
G
Ma
Kai
K
Chen
Yangxiang
Y
Liu
Xiaohong
X
Wu
Kejing
K
Ying
Ruifeng
R
Zhang
D000328:Adult; D004247:DNA / Q000235:genetics*; D004252:DNA Mutational Analysis; D006801:Humans; D008297:Male; D009154:Mutation; D017346:Protein Serine-Threonine Kinases / Q000235:genetics* / Q000378:metabolism; D011668:Pulmonary Veno-Occlusive Disease / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism; D014057:Tomography, X-Ray Computed
D004247:DNA; C529271:EIF2AK4 protein, human; D017346:Protein Serine-Threonine Kinases
Am J Pathol. 2015 Feb;185(2):356-71
25497573
Biochem Biophys Res Commun. 2011 Nov 11;415(1):120-4
22020073
Cell Cycle. 2007 Nov 15;6(22):2768-72
17986863
Cell Cycle. 2008 Aug;7(15):2346-51
18677106
Am J Physiol Lung Cell Mol Physiol. 2012 Mar 15;302(6):L604-15
22227206
PLoS One. 2010 Dec 21;5(12):e15716
21203563
EMBO J. 2006 Apr 19;25(8):1730-40
16601681
EMBO J. 2010 Jun 16;29(12):2082-96
20473272
Chest. 2000 Dec;118(6):1671-9
11115457
Circulation. 2015 Sep 1;132(9):834-47
26130118
Medicine (Baltimore). 2008 Jul;87(4):220-33
18626305
FEBS J. 2009 Feb;276(3):707-18
19120448
Eur Respir J. 2009 Dec;34(6):1348-56
19541723
Mol Cell Biol. 2007 Aug;27(16):5776-89
17576816
Eur Heart J. 2016 Jan 1;37(1):67-119
26320113
Chest. 2014 Feb;145(2):231-6
24135949
Nat Genet. 2014 Jan;46(1):65-9
24292273
Neoplasia. 2010 Jan;12 (1):61-8
20072654
Eur Respir J. 2015 Dec;46(6):1721-31
26541523
Am J Surg Pathol. 2006 Jul;30(7):850-7
16819327
Eur Respir J. 2009 Jan;33(1):189-200
19118230
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1681-5
9603154